



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

January 23, 2023

Robb Knie  
Chief Executive Officer  
Hoth Therapeutics, Inc.  
1 Rockefeller Plaza, Suite 1039  
New York, New York 10020

**Re: Hoth Therapeutics, Inc.**  
**Registration Statement on Form S-3**  
**Filed January 13, 2023**  
**File No. 333-269224**

Dear Robb Knie:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Arzhang Navai at 202-551-4676 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Nazia J. Khan, Esq.